Actelion Adds to PAH Franchise with IV drug from GeneraMedix
Buying GeneraMedix’s IV formulation of epoprostenol allows Actelion to leverage its infrastructure and experience in PAH and strengthen its lead in this increasingly crowded market.
Buying GeneraMedix’s IV formulation of epoprostenol allows Actelion to leverage its infrastructure and experience in PAH and strengthen its lead in this increasingly crowded market.